Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Subcutaneous Nipocalimab in Healthy Participants
NCT04848558Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nipocalimab in generalized myasthenia gravis (gMG) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Participants with Adverse Events, Percentage of Participants with Serious Adverse Events and 4 more. Started May 2021; status: completed.
02
Drugs
nipocalimab
03
Conditions
generalized myasthenia gravis (gMG)
Beyond the preview
Go deeper on NCT04848558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04848558.